Recent extragonadal FSHR expression findings opened up novel possibilities for functional FSHR as a diagnostic, prognostic, and therapeutic tool for cancer therapy (Siraj et al. 2013; Radu et al. 2010; Sheng et al. 2022; Starzynski et al. 2023), potentially also for postmenopausal obesity (Liu et al. 2015, 2017) bone mass/osteoporosis (Sun et al. 2006; Zhu et al. 2012), angiogenesis (Stilley et al., 2014b) or Alzheimer disease (Xiong et al. 2022). The gene discussed is FSHR; the disease is osteoporosis.